Clinical Trials Search
Clinical Trial 20082
Cancer Type: Malignant Hematology
Study Type: Treatment
NCT#: NCT03728335
Phase: N/A
Prinicipal Investigator: Nelli Bejanyan
Study Title
Pilot Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients with IDH2 Mutation
Summary
This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Objective
Primary Objective Evaluate the safety and tolerability of Enasidenib as post HCT maintenance therapy in patients with IDH2+ AML. Secondary Objective Assess overall and leukemia free survival in patients post allogeneic HCT; and Estimate relapse incidence, non-relapse mortality, GVHD and relapse free survival (GRFS) in patients receiving Enasidenib maintenance therapy.
Therapies
Medications
Enasidenib ()
Inclusion Criteria:
Exclusion Criteria:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.